Efficacy and Safety of Xiaoyao Formula as an Adjuvant Treatment for Post-Stroke Depression: A Meta-Analysis

    loading  Checking for direct PDF access through Ovid



To systematically evaluate the efficacy and safety of Xiaoyao formula (XYF) as an adjuvant treatment of post-stroke depression (PSD) by conducting a meta-analysis.


Pubmed, Embase, Cochrane Library, CNKI, VIP, and Wanfang databases were searched up to May 2016. Randomized controlled trials investigating XYF plus antidepressants versus antidepressants alone for patients with PSD were considered.


A total of 607 PSD patients were identified from 7 trials. Adjuvant treatment with XYF had additional benefits in terms of improved total response rates (risk ratio [RR] 1.21; 95% confidence interval [CI]: 1.12–1.30), reduced Hamilton's depressive scale (weighted mean difference [WMD] −5.21; 95% CI: −7.48 to −2.95), and decreased Scandinavian Stroke Scale (WMD −6.35; 95% CI: −8.27 to −4.43). No serious adverse events were observed in any of the included trials.


Adjuvant treatment with XYF appears to have additional benefits in the treatment of PSD, without increasing serious adverse events.

Related Topics

    loading  Loading Related Articles